Lubrizol’s Apisolex™ Polymer Wins Finished Formulation Award at CPhI Barcelona

27 October 2023 | Friday | News

Solubility-enhancing Excipient for Injectable Drug Formulations Wins Prestigious CPhI Barcelona Award
Image Source : Public Domain

Image Source : Public Domain

Lubrizol Life Science Health, a leading pharmaceutical company, has won the Finished Formulation Award at CPhI Barcelona for its innovative technology – Apisolex™ Polymer solubilizing excipient. With over 180 entries covering 12 innovation categories featuring many of pharma’s biggest names, Apisolex Polymer was again recognized as a breakthrough innovation adding to the prestigious award recognized by The Medicine Maker earlier this year. The winners were announced at a networking reception held at CPhI Barcelona with over 500 guests in attendance.


Apisolex™ Polymer is the first solubility-enhancing excipient to be launched specifically for parenteral use in over 20 years. Comprised of building blocks naturally occurring in the body, Apisolex™ is a poly(amino acid)--based excipient that provides drug formulators with the necessary tools and methods to enhance the solubility of hydrophobic APIs by up to 50,000-fold.


Approximately 60% of new chemical entities (NCEs) under development, and more than 40% of Active Pharmaceutical Ingredients (APIs) in reformulation are poorly water-soluble with each requiring tailored solutions. With several solubilizing excipients on the market, it is impossible to find a one-size-fits-all solution. Filling a crucial gap in the market, Apisolex™ Polymer enables novel brick-dust and grease ball APIs to be formulated, as well as providing existing APIs with the option to be repurposed or reformulated via the FDA’s 505(b)(2) regulatory pathway.


“By drawing on our 40+ year legacy, Lubrizol Life Science Health has developed a non-immunogenic, biocompatible, and biodegradable alternative to PEG-based excipients. Apisolex™ Polymer offers oncology, CNS, and high-value orphan drug formulators the tools necessary to unlock the potential of previously hard-to-formulate APIs, providing patients with access to life-changing therapeutics that otherwise may not have made it to market.” - Gaurab Sengupta, Senior Global Business Director, Pharmaceuticals & Nutraceuticals, Lubrizol Life Science Health.


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in